Theriva Biologics (NYSEAMERICAN:TOVX) Given New $6.00 Price Target at Maxim Group

Theriva Biologics (NYSEAMERICAN:TOVX) had its price objective cut by Maxim Group from $25.00 to $6.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Theriva Biologics Stock Up 0.7 %

Shares of Theriva Biologics stock opened at $1.36 on Wednesday. Theriva Biologics has a twelve month low of $1.24 and a twelve month high of $17.11. The stock has a market cap of $3.09 million, a PE ratio of -0.04 and a beta of 1.34.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.